Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort-Reference-Cited by-同舟云学术

Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort

Published:2017-07-16 Issue:12 Volume:31 Page:2046-2054
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Sbidian E.¹²³,Giboin C.⁴,Bachelez H.⁵,Paul C.⁶,Beylot-Barry M.⁷,Dupuy A.⁸,Viguier M.⁹,Lacour J.-P.¹⁰,Schmutz J.-L.¹¹,Bravard P.¹²,Mahé E.¹³,Beneton N.¹⁴,Misery L.¹⁵,Delaporte E.¹⁶,Modiano P.¹⁷,Barbarot S.¹⁸,Regnier E.¹⁹,Jullien D.²⁰,Richard M.-A.²¹,Joly P.²²,Tubach F.⁴²³²⁴,Chosidow O.¹²³

Affiliation:

1. Département de Dermatologie; AP-HP; Hôpitaux Universitaires Henri Mondor; UPEC; Créteil France

2. INSERM; Centre d'Investigation Clinique 1430; Créteil France

3. EA 7379 EpidermE; Université Paris-Est Créteil (UPEC); Créteil France

4. Département Biostatistique, Santé Publique et Information Médicale; Centre de Pharmaco-épidémiologie; CIC 1421; AP-HP; Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix; Paris France

5. Service de Dermatologie; Institut Imagine; AP-HP Hôpital Saint-Louis; INSERM UMR 1163; SorbonneParis Cité Université Paris Diderot; Paris France

6. Département de Dermatologie; Hôpitaux Universitaires de Toulouse; UMR INSERM 1056; Université Paul Sabatier; Toulouse France

7. Département de Dermatologie; INSERM U1053; Hôpital Saint-André; Université de Bordeaux; Bordeaux France

8. Département de Dermatologie; INSERM CIC 1414; Centre Hospitalier Universitaire de Rennes; Hôpital Pontchaillou; Université de Rennes 1; Rennes France

9. Département de Dermatologie; Hôpitaux Universitaires Robert Debré; Reims France

10. Département de Dermatologie; Centre de Référence Maladies Rares; Hôpital l'Archet 2; Centre Hospitalier Universitaire de Nice; Nice France

11. Département de Dermatologie et Allergologie; Hôpitaux de Brabois; Centre Hospitalier Régional Universitaire de Nancy; Nancy France

12. Département de Dermatologie; Groupe Hospitalier du Havre; Le Havre France

13. Département de Dermatologie; Hôpital Victor Dupouy; Argenteuil France

14. Département de Dermatologie; Centre Hospitalier du Mans; Le Mans France

15. Département de Dermatologie; Centre Hospitalier Régional Universitaire de Brest; Brest France

16. Département de Dermatologie; Centre Hospitalier Régional Universitaire de Lille; Lille France

17. Département de Dermatologie; Groupement des Hôpitaux de l'Institut Catholique de Lille; Hôpital Saint-Vincent-de-Paul; Lille France

18. Département de Dermatologie; Centre Hospitalier Universitaire de Nantes; Nantes France

19. Département de Dermatologie; AP-HP; Hôpitaux Universitaires Cochin; Université Paris Descartes Paris V; Paris France

20. Département de Dermatologie; HCL; Centre Hospitalier Universitaire; Hôpital Edouard Herriot; Lyon France

21. Département de Dermatologie; Centre Hospitalier Universitaire; Hôpital La Timone; Marseille France

22. Department of Dermatology; Rouen University Hospital; INSERM U 1234; Normandie University; Rouen France

23. Université Pierre et Marie Curie; Sorbonne Universités; Paris France

24. UMR 1123; CIC 1421; ECEVE; INSERM; Paris France

Funder

French Ministry of Health

French Agency for Drugs (ANSM)

AbbVie

Janssen

Pfizer

Meso Scale Diagnostics

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14406/fullpdf

Reference16 articles.

1. Global epidemiology of psoriasis: a systematic review of incidence and prevalence;Parisi;J Invest Dermatol,2013

2. European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC;Nast;J Eur Acad Dermatol Venereol,2015

3. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review;Spuls;J Invest Dermatol,2010

4. NICE guidelines www.nice.org.uk

5. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis;Fenix-Caballero;J Clin Pharm Ther,2013

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of Patients With Psoriasis Treated With Various Biologics – A Danish Cohort Study;Journal of Psoriasis and Psoriatic Arthritis;2024-02-19

2. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-29

3. Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort;Clinical and Experimental Dermatology;2023-07-06

4. Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort;Annales de Dermatologie et de Vénéréologie;2023-06

5. CITY-PSO: Prescribing behaviour of French private-practice dermatologists in psoriasis management: An observational, multicentre, cross-sectional study;Annales de Dermatologie et de Vénéréologie;2022-09